Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as
effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic
events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic
deep venous thrombosis (DVT) and to assess its safety (bleedings) versus warfarin.